Are you experiencing relationship troubles? It's not because the love is gone, it's because of BURNOUT! Watch for expert remedies (not AI), plus the paraphrasing rule that saves arguments nearly every time! Dr. Mindy DeSeta of https://Insight-Miami.com has great, expert advice.

New FDA-Accelerated approval for BEQALZI pill to treat Mantle Cell Lymphoma cancers that are resistant to or recur with older treatments. Watch video podcast with expert, Michael Wang, M.D. , who explains the disease and BEQALZI made by BeOne Medicines.DoctorPodcasts EPISODE 170 Timeline/ Chapters: - Introduction & Welcome - Meet Dr. Michael Wang (MD Anderson Cancer Center) - What Is Lymphoma? (Liquid Cancers vs. Solid Tumors) - What Makes Mantle Cell Lymphoma Unique & Difficult to Treat? - Who Gets Mantle Cell Lymphoma? (Demographics & Risk Factors) - Symptoms of Mantle Cell Lymphoma - How MCL Is Diagnosed: Biopsies, Markers & Flow Cytometry - The Evolution of Treatment: Moving Beyond Chemotherapy - Targeted Therapies: BTK Inhibitors & CAR T-Cell Therapy - Understanding BCL-2 Inhibitors in Cancer Mitochondria - BEQALZI (Sonrotoclax): Breakthrough BCL-2 Inhibitor - What Is FDA Accelerated Approval? - BEQALZI Clinical Trial Results & Response Rates - Dosing & Treatment Duration (Once-Daily Pill) - Availability & Sonrotoclax vs. Venetoclax - BeOne Medicines & Global Collaboration - Conclusion & Closing Remarks

Leading breast cancer specialist and medical oncologist, Robert Wesolowski, M.D. of the Ohio State University Comprehensive Cancer Center breaks down the latest breakthroughs in breast cancer treatment, including the newly FDA-approved targeted drug REVTORPYK (gedatolisib / Celcuity), how genetic markers like BRCA1 & BRCA2 guide care, and what the future of AI looks like in oncology.🔔 Subscribe to DoctorPodcasts: Don't forget to like this DoctorPodcasts Episode 171 video, leave a comment with your thoughts or questions, and share this episode with anyone navigating breast cancer treatment!⏱️ TIMESTAMPS & CHAPTERS:00:00 - Introduction & Meet Dr. Robert Wesolowski01:35 - Breast Cancer Statistics & Trends in Younger Populations04:03 - The 3 Main Subtypes: HR+, HER2+, & Triple-Negative06:50 - How Survival Rates & Outlook Have Transformed07:46 - BRCA1 vs. BRCA2 Genes: What Are the Risks?09:43 - Who Should Get Genetic Testing & Counseling?11:07 - Surgery vs. Radiation vs. Chemotherapy Decision Making14:09 - The Power of Neoadjuvant Chemotherapy & Targeted Drugs16:24 - REVTORPYK Breakthrough: Mechanism, Clinical Trial Data & FDA Approval19:17 - Administration Schedule & Managing Side Effects21:25 - How AI Is Revolutionizing Global Breast Cancer Care23:18 - Closing Remarks⚠️ Medical Disclaimer:This video podcast is for educational and informational purposes only and does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician regarding a medical condition.#BreastCancer #Oncology #REVTORPYK #CancerResearch #BRCA #WomensHealth #CancerTreatment #cancer #Cykiert #Celcuity #DoctorPodcasts

What is ZIIHERA, and how is this newly FDA-approved targeted therapy transforming the treatment of advanced HER2-positive gastroesophageal cancer?

In this episode 168 of DoctorPodcasts: Cykiert Files, host Dr. Robert Cykiert is joined by two world-renowned oncology experts: • Dr. Geoffrey Ku – Associate Attending Physician, Gastrointestinal Oncology Service at Memorial Sloan Kettering Cancer Center (MSKCC) & Phase 3 trial investigator. • Dr. Robert Iannone – Executive Vice President, Global Head of R&D, and Chief Medical Officer at Jazz Pharmaceuticals.

Together, they break down the groundbreaking science behind ZIIHERA, the landmark HORIZON-GEA-01 Phase 3 trial results, managing treatment side effects (including diarrhea prophylaxis), biomarker testing (HER2 & PD-L1), and what this means for patients with metastatic and locally advanced esophageal, GE junction, and gastric adenocarcinoma cancers.

📌 In This Episode, You’ll Learn: • What gastroesophageal adenocarcinoma (GEJ cancer) is and key risk factors (acid reflux, Barrett’s esophagus, H. pylori). • How ZIIHERA’s unique bispecific HER2 antibody mechanism differs from standard therapies like Herceptin (trastuzumab). • Key survival and progression-free survival findings from the HORIZON-GEA-01 Phase 3 study. • Why ZIIHERA combined with immunotherapy benefits patients regardless of PD-L1 status. • Essential clinical guidance on managing and preventing GI side effects. • Why comprehensive biomarker and HER2 testing is vital for every patient.

⏱️ TIMELINE / CHAPTERS:

00:00 - Introduction to Gastroesophageal Cancer & ZIIHERA

00:43 - Introducing Dr. Geoffrey Ku (MSKCC) & Dr. Robert Iannone (Jazz Pharmaceuticals)

02:16 - What is Gastroesophageal Adenocarcinoma (GE Junction & Stomach Cancer)?

03:27 - Risk Factors: Acid Reflux, Barrett’s Esophagus, Obesity & H. Pylori

06:43 - Why Esophageal and Stomach Cancers Are Often Diagnosed Late

09:17 - Understanding HER2-Positive Cancer & Key Biomarkers (PD-L1, MMR, Claudin 18.2)

12:25 - Evolution of 1st-Line Treatment: Chemo, Trastuzumab & Immunotherapy

14:06 - How ZIIHERA (Zanidatamab) Was Developed & Mechanism of Action

17:03 - Biliary Tract Cancer Approval to Gastroesophageal Phase 3 Trials

19:30 - HORIZON-GEA-01 Phase 3 Trial Design & FDA Approval Indications

20:56 - Efficacy Across PD-L1 Positive and Negative Patients

22:20 - Metastatic vs. Locally Advanced Disease & Potential Curative Setting

26:13 - Safety Profile & Managing Side Effects (Diarrhea Prophylaxis Protocols)

31:08 - Cardiac Monitoring & Drug Tolerability

31:47 - Dosing, Administration Route & Treatment Duration

33:28 - Overall Survival & Progression-Free Survival Data Breakdown

39:16 - Patient Quality of Life During Treatment

40:17 - Encouragement for Patients & Families Considering Targeted Therapy

44:06 - Nationwide Availability & Global Regulatory Status (Project Orbis)

46:11 - The Critical Importance of Routine HER2 Biomarker Testing

48:11 - Future Applications of ZIIHERA & Jazz Pharmaceuticals Oncology Pipeline

51:09 - Concluding Remarks & Summary

🔔 Please subscribe to DoctorPodcasts: Cykiert Files for expert discussions on medical breakthroughs, clinical trials, and healthcare innovations.

Disclaimer: This video podcast is for educational and informational purposes only and does not constitute personalized medical advice. Please consult your physician or qualified healthcare provider regarding specific medical conditions or treatments.

#EsophagealCancer #ZIIHERA #StomachCancer #Oncology #CancerResearch #HER2Positive #Immunotherapy #CancerBreakthrough #MedicalPodcast #JazzPharmaceuticals #Cykiert #DoctorPodcasts

In this episode 167 of DoctorPodcasts: Cykiert Files, we explore the groundbreaking advancements in cancer therapy and how Sanofi’s new FDA-approved treatment Sarclisa Escena via a CirCLIQ On‑Body Injector https://pro.campus.sanofi/us/products/sarclisa is revolutionizing multiple myeloma patient care and improving patients' quality of life. It's also benefiting physician and healthcare provider efficiencies while reducing healthcare costs.Learn how this targeted therapy works from Mayo Clinic Multiple Myeloma expert, Sikander Ailawadhi, M.D., https://www.mayoclinic.org/biographies/ailawadhi-sikander-m-d/bio-20087330, the clinical data behind its approval, and what this means for patients, oncologists, and the future of oncology treatments.⏱️ TIMESTAMPS / CHAPTERS00:00 - Introduction to Multiple Myeloma & Recent Breakthroughs03:15 - What is Multiple Myeloma? (Disease Overview)07:45 - The Science Behind Sanofi’s FDA-Approved Treatment12:30 - Key Clinical Trial Results & Patient Outcomes18:10 - How This Treatment Compares to Standard of Care23:40 - Future Outlook for Multiple Myeloma Therapies28:10 - Final Thoughts & Summary💬 JOIN THE CONVERSATIONHave questions about this new FDA approval or current cancer treatment advances? Drop your thoughts or questions in the comments below!👍 Like this video if you found it informative, and Subscribe to DoctorPodcasts: Cykiert Files for in-depth medical discussions, expert interviews, and healthcare breakthroughs.🔔 DISCLAIMERThe information provided in this video podcast is for educational and informational purposes only and is not intended as medical advice. Always consult a qualified healthcare professional regarding any medical condition or treatment.🏷️ HASHTAGS#MultipleMyeloma #CancerResearch #Oncology #FDAApproval #CancerTreatment #MedicalBreakthrough #DoctorPodcasts #CirCLIQ #On-Body Injector#Sanofi #Sarclisa #Sarclisa Escena #Cykiert

Colon-rectal cancer is one of the leading causes of cancer-related deaths, yet it is highly treatable and preventable when detected early. Three world-renowned experts discuss the latest breakthroughs in non-invasive colon cancer screening, including at-home @Cologuard stool DNA tests and newly FDA-approved @Freenome blood tests.00:00 - Introduction: The Power of Non-Invasive Screening 02:36 - Welcome & Meet the Expert Panel 06:31 - Colorectal Cancer Trends & The Rise in Under-50 Cases 08:30 - Early Warning Signs vs. Asymptomatic Colon Cancer 09:09 - Why Screening Guidelines Lowered the Age to 45 10:40 - Why Do People Delay or Avoid Colonoscopies? 12:45 - What Is Cologuard & Multi-Target Stool DNA Testing? 15:10 - Who Is Eligible for Non-Invasive Screening? 16:04 - Step-by-Step: The At-Home Cologuard Experience 17:36 - Do At-Home Tests Replace a Colonoscopy? 18:47 - Accuracy & Clinical Data 20:23 - Patient Adherence Rates & Common Misconceptions 22:58 - Riley Ennis & The Story Behind Freenome 24:05 - How SimpleScreen CRC Uses Multiomics & AI 25:34 - SimpleScreen CRC Accuracy & PREEMPT CRC Trial Data 27:02 - Where Blood Tests Fit in the Screening Cascade 28:24 - Overview of New FDA-Approved Non-Invasive Options 29:07 - Cologuard vs. Cologuard Plus: What Changed? 30:05 - Can Stool and Blood Tests Be Combined? 31:22 - Awareness Campaigns & Educating the Public 33:06 - The Future of Colonoscopies & Early Detection 34:43 - Beyond CRC: Multi-Cancer Early Detection (Lung & Pancreas) 36:26 - Insurance & Medicare Coverage Explained 38:52 - Final Takeaways & Advice for Patients

In this episode 165 of the DoctorPodcasts show, host Dr. Robert Cykiert video interviews board-certified plastic surgeon Dr. Nirmal Nathan, founder of the Nathan Clinic in Miami, Florida to break down the massive cultural and medical shifts defining modern cosmetic surgery. From the rapid rise of GLP-1 weight loss drugs like Ozempic, Wegovy, Mounjaro, and Zepbound to the reality behind "Ozempic Face, Skin and Body," Dr. Nathan pulls back the curtain on how plastic surgeons address sagging skin without causing the dreaded "wind tunnel" look. They also dive into why millions of men are turning to cosmetic surgery in the post-COVID "Zoom Boom," the truth about secret $100K celebrity procedures, and the real life-threatening dangers of low-regulated medical tourism overseas. Whether you’re curious about deep plane facelifts, the evolution of social media beauty standards, or how conditions like diabetes impact surgical safety, this deep-dive interview provides expert clinical insights you won't find anywhere else. Subscribe to DoctorPodcasts for more exclusive medical interviews, health trends, and expert insights:⏳ TIMESTAMPS 0:00 - Introduction & Meet Top Plastic Surgeon Dr. Nurmal Nathan2:48 - The Family Legacy: Growing Up Watching Facial Reconstruction5:01 - Inside the Training of a Top Plastic Surgeon (UCSF & Miami Volume)7:05 - From Nip/Tuck to the Kardashians: What is Driving the Plastic Surgery Boom?8:14 - The COVID "Zoom Boom" & The Massive Rise of Men's Plastic Surgery9:34 - Celebrity Plastic Surgery vs. Social Media Influence: What Sets the Trends?11:05 - The Truth About $100k "Secret" Procedures & Plastic Surgery Arbitrage12:48 - The Real Dangers of Medical Tourism (Botched Work Overseas)15:28 - The GLP-1 Weight Loss Revolution (Ozempic, Wegovy, Mounjaro)17:03 - Understanding "Ozempic Face" & Advanced Facial Aging18:26 - How Deep Plane Facelifts Tighten Sagging Skin Safely (Avoiding the Wind Tunnel Look)19:03 - The "Goldilocks Sweet Spot": When Is It Safe to Get Surgery After Weight Loss?21:13 - Medical Optimization: Why a Hemoglobin A1C Under 7 Matters for Healing